Ameriprise
KALA icon

Ameriprise’s KALA BIO KALA Stock Holding History

Ameriprise’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21
Closed -$509K – 3711
2018
Q3 		$509K Sell
21
-5
-19% -$152K ﹤0.01% 3289
2018
Q2 		$893K Buy
26
+2
+8% +$76.7K ﹤0.01% 3055
2018
Q1 		$937K Buy
24
+6
+33% +$228K ﹤0.01% 2998
2017
Q4 		$834K Buy
18
+8
+80% +$374K ﹤0.01% 3053
2017
Q3 		$562K Buy
+10
New +$549K ﹤0.01% 3180

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Ameriprise's KALA Position: Q4 2018 in Review

Ameriprise sold out of KALA BIO (KALA) in Q4 2018, closing a stake of 21 shares — an estimated $509K sold.

Ameriprise first reported a position in KALA in Q3 2017 and held it in 5 quarters. The position peaked at $937K in Q1 2018. 64 funds tracked by Wall St. Rank hold KALA as of Q4 2018.

  • Ameriprise reported no remaining KALA BIO position as of Q4 2018 after selling out during the quarter.
  • Ameriprise sold 21 KALA BIO shares in Q4 2018, an estimated $509K.
  • Ameriprise first reported a position in KALA BIO in Q3 2017 and held it in 5 quarters.
  • Ameriprise's KALA BIO position peaked at $937K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held KALA BIO as of Q4 2018.

Based on Ameriprise's 13F filing for Q4 2018, filed 14 Feb 2019.